We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now
Read MoreHide Full Article
Key Takeaways
IQVIA shares rose 15.3% in a year, outperforming the industry's drop of 7.1%.
IQVIA posted a record $34.2B backlog; $8.9B should convert to revenues in the next 12 months.
IQV deployed 192 AI agents in 64 use cases; 19 of the top 20 pharma firms use them in workflows.
Shares of IQVIA Holdings Inc. (IQV - Free Report) have risen 15.3% over the past year against the industry’s 7.1% fall.
IQV’s revenues are expected to increase 5.7% and 5.9% year over year in 2026 and 2027, respectively. Earnings are anticipated to rise 7.2% in 2026 and 11.1% in 2027.
Factors That Augur Well for IQV’s Success
Record Backlog: During the first quarter of 2026 earnings call, Ari Bousbib, the CEO, stated that IQV’s backlog reached a new record of $34.2 billion. Out of the total backlog, $8.9 billion is anticipated to convert to revenues over the upcoming 12 months. It represents approximately 8% year-over-year growth compared with the recast numbers from the preceding year.
AI Fueling Demand: Rapid AI adoption by IQVIA’s clients has increased demand for the company’s differentiated, health-grade capabilities. The company has deployed 192 specialized AI agents across 64 distinct use cases. Importantly, 19 out of the top 20 pharma companies are leveraging these agents within their workflows. IQV successfully managed to secure multi-year partnerships utilizing AI-led data foundations and Data-as-a-Service platforms with Pfizer, Boehringer Ingelheim and many more.
Active Share Repurchase: IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2025, the company repurchased shares worth $1.24 billion. This substantial buyback not only lowers the total outstanding share count, thereby increasing earnings per share, but also signals management's confidence in the intrinsic value of the stock.
Risks Faced by IQVIA
Weak Liquidity Profile: IQVIA’s current ratio at the end of the first quarter of 2026 was 0.75, lower than the industry’s 1.79. A current ratio of less than 1 highlights the fact that the company may have problems paying off its short-term obligations.
Image Source: Zacks Investment Research
No Dividends: The company neither pays dividends nor currently has any plans to do so in the future. Payment of dividends in the future depends on factors such as its financial condition, cash requirements and contractual restrictions. Investors seeking cash dividends should avoid buying IQVIA stock.
IQV’s Zacks Rank & Stocks to Consider
The company has a Zacks Rank #3 (Hold) at present.
Bayer has a long-term earnings growth expectation of 2.5%. BAYRY delivered a trailing four-quarter earnings surprise of 23.6%, on average.
Alignment Healthcare has a long-term earnings growth expectation of 38%. ALHC delivered a trailing four-quarter earnings surprise of 198.8%, on average.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now
Key Takeaways
Shares of IQVIA Holdings Inc. (IQV - Free Report) have risen 15.3% over the past year against the industry’s 7.1% fall.
IQV’s revenues are expected to increase 5.7% and 5.9% year over year in 2026 and 2027, respectively. Earnings are anticipated to rise 7.2% in 2026 and 11.1% in 2027.
Factors That Augur Well for IQV’s Success
Record Backlog: During the first quarter of 2026 earnings call, Ari Bousbib, the CEO, stated that IQV’s backlog reached a new record of $34.2 billion. Out of the total backlog, $8.9 billion is anticipated to convert to revenues over the upcoming 12 months. It represents approximately 8% year-over-year growth compared with the recast numbers from the preceding year.
AI Fueling Demand: Rapid AI adoption by IQVIA’s clients has increased demand for the company’s differentiated, health-grade capabilities. The company has deployed 192 specialized AI agents across 64 distinct use cases. Importantly, 19 out of the top 20 pharma companies are leveraging these agents within their workflows. IQV successfully managed to secure multi-year partnerships utilizing AI-led data foundations and Data-as-a-Service platforms with Pfizer, Boehringer Ingelheim and many more.
Active Share Repurchase: IQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2025, the company repurchased shares worth $1.24 billion. This substantial buyback not only lowers the total outstanding share count, thereby increasing earnings per share, but also signals management's confidence in the intrinsic value of the stock.
Risks Faced by IQVIA
Weak Liquidity Profile: IQVIA’s current ratio at the end of the first quarter of 2026 was 0.75, lower than the industry’s 1.79. A current ratio of less than 1 highlights the fact that the company may have problems paying off its short-term obligations.
No Dividends: The company neither pays dividends nor currently has any plans to do so in the future. Payment of dividends in the future depends on factors such as its financial condition, cash requirements and contractual restrictions. Investors seeking cash dividends should avoid buying IQVIA stock.
IQV’s Zacks Rank & Stocks to Consider
The company has a Zacks Rank #3 (Hold) at present.
Some top-ranked stocks from the broader Zacks Medical sector are Bayer (BAYRY - Free Report) and Alignment Healthcare (ALHC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bayer has a long-term earnings growth expectation of 2.5%. BAYRY delivered a trailing four-quarter earnings surprise of 23.6%, on average.
Alignment Healthcare has a long-term earnings growth expectation of 38%. ALHC delivered a trailing four-quarter earnings surprise of 198.8%, on average.